Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a total of nearly $4 billion in cash. This move aims to expand Eli Lilly's research and development efforts into infectious diseases, focusing on preventing diseases at their source. The acquisitions are valued at $1.5 billion, $780 million, and $1.55 billion respectively. Following the announcement, Eli Lilly's shares rose 1.3% in premarket trading, reflecting positive investor sentiment on the company's strategic expansion.
The global GLP-1 receptor agonist market, used primarily for type 2 diabetes and obesity management, is projected to grow from $28.7 billion in 2025 to $95.3 billion by 2035, at a compound annual growth rate of 12.1%. Growth is fueled by rising diabe...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The Frost & Sullivan Institute has recognized 50 leading companies with the 2026 Visionary Growth Leadership Best Practices Recognition for embedding innovation, measurable impact, and sustainability into their growth strategies. These companies, inc...
Eli Lilly announced positive Phase 1 results for AJ1-11095, a novel type II JAK2 inhibitor targeting myelofibrosis patients who failed type I JAK2 inhibitors. The drug demonstrated a strong safety profile, significant spleen size reduction, symptom i...
At the American Diabetes Association conference, leading drugmakers like Eli Lilly and Novo Nordisk showcased new obesity treatments including advanced GLP-1 pills and shots promising greater weight loss and easier dosing schedules. Eli Lilly's exper...
